Shifting Focus: From Healthcare to AI-Driven Health Management
TORONTO, February 12, 2025--(BUSINESS WIRE)--Predictmedix AI (CSE: PMED | OTC: PMEDF | FRA: 3QP) (the "Company" or "Predictmedix") is repositioning itself as an emerging leader in AI-powered health management technologies, with a strategic shift toward solutions that go beyond traditional healthcare. The Company’s approach emphasizes workplace safety, workforce readiness, and public sector health screening—areas where AI-driven technologies can potentially offer scalable, impactful solutions without the regulatory complexities associated with traditional healthcare.
The Company is repositioning its technologies to focus on real-time health screening and workforce monitoring, aiming to address emerging needs in industries where safety and operational efficiency are critical.
AI-Driven Solutions for Enterprise "Fit-for-Duty" Screening
Predictmedix AI is advancing screening solutions intended to help businesses gain insights into workforce readiness by detecting factors such as fatigue, monitoring vital signs, and identifying signs of substance induced impairment.
These solutions are designed for industries where safety and compliance are essential—including manufacturing, logistics, energy, construction, and defense. The technology is being advanced to integrate with HR, compliance, and safety protocols, offering a potential pathway to reduce risks, improve operational efficiency, and support safety initiatives.
AI-Driven Health Monitoring for Public Sector and Institutions
The Company is assessing opportunities to introduce its technology in defense, public safety, and education sectors, aimed at enhancing workplace health monitoring applications through screening for physiological parameters, AI-driven assessments for law enforcement & military personnel along with public sector health monitoring initiatives focused on workforce readiness. These technologies have the potential to support organizations in assessing physical and mental preparedness while promoting public health strategies.
"Our strategic focus on AI-driven health management represents a significant advancement," said Dr. Rahul Kushwah, COO of Predictmedix AI. "Our solutions focus on delivering valuable real-time health insights aimed at improving workforce readiness and safety. Furthermore, they are being advanced to integrate seamlessly with existing HR and compliance systems, with the goal of fostering efficient adoption and minimizing disruptions compared to traditional approaches."
Predictmedix AI is currently focused on advancing its technological capabilities and exploring opportunities for enterprise and public sector adoption. The Company’s data-driven health management technologies aim to offer scalable solutions for organizations seeking real-time health insights without the need for invasive testing.
Further updates will be provided as the Company progresses with its strategic positioning.
Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company’s Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI’s proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.
Caution Regarding Forward-Looking Information:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time."
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
